HighLife Raises $90M+ for US Trial & European Expansion

HighLife SAS, a prominent player in transcatheter structural heart disease solutions, has successfully closed a significant funding round exceeding $90 million (€80 million). This substantial capital infusion is earmarked to propel the company's pivotal clinical study in the United States and accelerate its commercial rollout across European markets.

The financing round saw robust participation from a consortium of leading investors, underscoring strong confidence in HighLife's innovative technology. The round was co-led by Andera Partners, Sofinnova Partners, Supernova Invest, and Mérieux Equity Partners. A notable group of new backers also joined, including the European Investment Bank, BNP Paribas Développement, Capricorn Partners, Critical Path Ventures, Pro Benefis Familiae, and SPRIM Global Investments Ltd., alongside a global strategic investor. Existing shareholders, including USVP, Sectoral, and VI Partners, also reaffirmed their commitment through participation.

This funding arrives at a critical juncture for HighLife, following key regulatory achievements. The company secured CE Mark approval for its Transcatheter Mitral Valve Replacement (TMVR) system earlier this year, paving the way for a limited European market release. Crucially, this approval also greenlit the commencement of its pivotal US clinical trial. Furthermore, HighLife recently obtained CE Mark for its next-generation Clarity Valve, specifically engineered to minimize left ventricular outflow tract (LVOT) obstruction, a persistent challenge in TMVR adoption. These advancements collectively enhance patient access to advanced treatment options for mitral regurgitation.

The mitral valve repair and replacement market is experiencing dynamic growth, driven by an aging population and increasing prevalence of structural heart conditions. The total addressable market for mitral valve interventions is projected to reach billions of dollars in the coming years, with transcatheter approaches gaining significant traction due to their minimally invasive nature. HighLife's valve-in-ring concept, designed to replicate surgical outcomes via a transfemoral approach, positions it to capture a substantial share of this expanding market, particularly for patients unsuitable for traditional surgery or less invasive edge-to-edge repair techniques.

Stefan Pilz, Chief Executive Officer of HighLife, emphasized the strategic importance of this financing. "This capital injection marks a pivotal moment as we solidify our technology as a vital new treatment avenue for patients suffering from severe mitral regurgitation with limited alternatives. It directly supports our strategic objectives: accelerating European commercialization, advancing our US pivotal study, and building an organization capable of sustained long-term growth," he stated.

Rémi Spagnol, Partner at Supernova Invest, a co-lead investor, added, "We are at an inflection point for transcatheter mitral valve replacement. HighLife's differentiated technology, coupled with its seasoned team and this robust financial backing, uniquely positions the company to emerge as a global leader in this transformative therapeutic field." The company's technology aims to address symptomatic moderate-to-severe or severe mitral regurgitation in adult patients who are not ideal candidates for open-heart surgery or transcatheter edge-to-edge repair.